Slope's SaaS platform manages end-to-end supply chain logistics for clinical trials, coordinating the movement of drugs, devices, and kits from suppliers to trial sites to patients in real time. The platform provides complete traceability and reduces operational complexity for trial sponsors.

We invested in Slope in 2020, impressed by the tenacious founders, Rust and Michael Felix, and their vision to reduce inefficiencies in clinical trials. They are addressing the costly roadblocks caused by supply chain issues in drug commercialization. Unlike traditional systems, Slope manages a fully traceable chain of custody for all clinical inventory, including lab kits and medical devices, which is crucial for data integrity and addresses the increasing use of non-drug supplies. This provides real-time visibility and helps manage resupply, a significant improvement over manual processes. Slope strategically targets Phase I and Phase II Oncology trials, a segment with high non-drug supply requirements and numerous clinical trials, differentiating itself from competitors focused on gene therapies.